GCG and type 2 diabetes mellitus: Semaglutide, a newly subcutaneous and long acting GLP-1 RA with 94% structural homology to native GLP-1, has been approved by the United States Food and Drug Administration (FDA) on December 5, 2017, as an adjunct to diet and exercise for the treatment of T2DM (Lau et al., 2015; Dhillon, 2018).